Australian biotechnology company, Living Cell Technologies has showcased its nanobiocapsule at a session on nanotechnology at NZBio in Auckland, New Zealand.
The nanobiocapsules allows encapsulated pig insulin producing cells, DiabeCell, to be implanted without the use of toxic immune suppressive drugs.

The company reported positive early preliminary data from an on-going phase I/IIa clinical trial, which shows that following implant into patients with insulin dependent diabetes, the encapsulated porcine pancreatic islets remain functioning for at least 6 months and beneficial effects were greater than expected.